HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 08, August 2019 – Digitalization vs Digitization — Exploring Emerging Trends in Healthcare       » Shanghai neurologists test brain implant to tackle drug addiction       » Gene-editing researchers reduce cancer risk       » Artificial Intelligence in Precision Cancer Diagnostics: Myth or Magic?       » Healing with Technology       » Smart Hospital: An Instrument of Care       » Transforming Healthcare with Data and Artificial Intelligence      
EYE ON CHINA
Bio-imaging breakthrough developed by China-Australia collaboration
Promising results from animal models show potential for further clinical trials.

A China-Australia research collaboration has resulted in a revolutionary new imaging contrast agent, with the potential for doctors see more deeply and clearly inside the body than ever before as they conduct internal surgeries.

Scientists from Fudan University in China and the University of Technology Sydney (UTS), combined forces to create the agent which so far has been tested on mice with very promising results.

"It's really about how we use optical agents to get better resolution and deeper penetration through the body," study senior author and director of the UTS Institute for Biomedical Materials and Devices, Professor Dayong Jin said.

The agent reacts to light in a way that when introduced to the human body should give doctors and surgeons a much clearer picture of what is occurring internally.

"From a medical point of view, this is very good for optical guided real time surgery. On tumors for example, the contrast agent will show the boundary between the tumor and healthy tissue with much higher resolution," Jin said.

While the method is yet to be tested on humans, Jin said it will allow doctors to use light rather than high intensity lasers to illuminate what they are operating on inside the body, making it much safer and less invasive for patients.

The partnership between Fudan University and UTS resulted when Jin travelled to China around five years ago, beginning a process of discussions to determine how the institutions can work together and combine their specialties.

UTS specialized in the physics side of design and detection, while scientists at Fudan manufactured the material and conducted animal testing.

"This research is not by accident, you know, this is a very logical design and progress in the past couple of years," Jin said.

The next step is to undergo further medical research, conducting ethical and procedural trials, to take this potentially revolutionary technology from the realms of physics, to lifesaving technology.

Source: Xinhua

Click here for the complete issue.

NEWS CRUNCH  
news How blockchain can save the food industry millions from recalls
news China Healthcare and Pharma Digital Innovation Summit
news BIO-PHARM2019 — The Most Influential Forum in China's Biopharm Industry
news The rise of personalised nutrition
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy